Novartis has announced a broad range of initiatives to respond to COVID-19 pandemic. This includes the creation of a $20 million global fund to support impacted communities and entering into new collaborative research efforts such as the COVID-19 Therapeutics Accelerator that is coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, as well as a COVID-19 directed partnership organized by the Innovative Medicines Initiative. Our company has also made available a set of compounds from its libraries that it considers suitable for in vitro antiviral testing and is evaluating its existing products to see if any could be repurposed beyond their approved indications.
This builds on our commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response, should the medicine prove effective in COVID-19. Sandoz was the first company to commit to keeping prices stable on the a basket of essential medicines under evaluation to treat COVID-19 in February.
Sandoz, a Novartis division and leading generics and biosimilar company, continues to deliver its medicines to patients and healthcare providers around the world and does not anticipate global supply chain disruption for the majority of its portfolio at this time given strong mitigation measures and inventory levels.
It is important to realize the situation is very dynamic and there are aspects that are beyond any one manufacturer’s control. We remain fully committed to working across the industry and with key stakeholders including the US and other governments, important organizations such as the WHO, AAM, MfE and others, as appropriate, to ensure adequate supply of critical medicines to all patients around the world.